Skip to main content
NPJ Breast Cancer logoLink to NPJ Breast Cancer
. 2023 Jul 24;9:62. doi: 10.1038/s41523-023-00567-6

Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial

Yang Yang 1, Yingjian He 1, Zhaoqing Fan 1,, Xue Chen 1, Yiqiang Liu 1, Chao Zhang 2, Hongchuan Jiang 2, Xin Wang 3, Xiang Wang 3, Fei Xie 4, Shu Wang 4, Bin Luo 5, Hua Kang 6, Tao Wang 7, Zefei Jiang 7, Peng Yuan 3, Binhe Xu 3, Ling Xu 8, Yinhua Liu 8, Jinfeng Li 1, Yuntao Xie 1, Tianfeng Wang 1, Tao Ouyang 1
PMCID: PMC10366133  PMID: 37488099

Correction to: npj Breast Cancer 10.1038/s41523-023-00553-y, published online 21 June 2023

“In this article the affiliation details for Author’s Jinfeng Li, Yuntao Xie, and Tianfeng Wang were incorrectly given as ‘Cancer Hospital, Chinese Academy of Medical Sciences, Breast Cancer Department, Beijing, China’ but should have been ‘Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China’. The original article has been corrected.“


Articles from NPJ Breast Cancer are provided here courtesy of Nature Publishing Group

RESOURCES